Drug
Fidaxomicin clinical trials
Also written Dificid, OPT-80 and PAR-101.
- studies test it
- 23
- open now
- 2
- in phase 3
- 6
- first study started
- 2004
Keep track of what changes. Save the Fidaxomicin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2012 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 6
- Phase 4
- 11
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 11
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (5) · Astellas Pharma Europe Ltd. (3) · Astellas Pharma Europe B.V. (2) · Astellas Pharma Inc (1) · University of Michigan (1) · Duke University (1) · Hartford Hospital (1) · Astellas Pharma Global Development, Inc. (1)
Often tested with
Tested in the same studies.
Vancomycin (6) · Metronidazole (1) · Rosuvastatin (1) · Fecal Microbiota Transplantation (1)
Studies
Open first, then newest update. How each study uses Fidaxomicin is read from its arms, and is right about nine times in ten.
Testing it · 23
- Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel DiseaseNot yet recruitingPhase 4Brigham and Women's HospitalNCT06794944Written as Fidaxomicin
- STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile InfectionNot yet recruitingNot applicableMedical University of WarsawNCT07120490Written as Fidaxomicin
- Optimal Treatment for Recurrent Clostridium DifficileTerminatedPhase 4VA Office of Research and DevelopmentNCT02667418Written as Fidaxomicin
- A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)CompletedPhase 3Astellas Pharma Europe B.V.NCT02218372Written as Fidaxomicin oral suspension
- Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)CompletedPhase 4Astellas Pharma Europe Ltd.NCT02437591Written as fidaxomicin
- A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older PopulationCompletedPhase 4Astellas Pharma Europe Ltd.NCT02254967Written as Fidaxomicin
- A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)CompletedPhase 3Astellas Pharma IncNCT02179658Written as OPT-80
- Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile InfectionTerminatedPhase 3McMaster UniversityNCT02395848Written as Fidaxomicin
- Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile InfectionTerminatedPhase 2University of AlbertaNCT03760484Written as Fidaxomicin 200 mg
- A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent InfectionsCompletedPhase 4University of MichiganNCT02692651Written as Fidaxomicin
- A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune SystemTerminatedPhase 4Astellas Pharma Europe Ltd.NCT01775397Written as Fidaxomicin
- Impact of Oral Antibiotic Treatment on C. DifficileCompletedPhase 4Duke UniversityNCT02057198Written as Fidaxomicin
- Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)CompletedPhase 3Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01691248Written as fidaxomicin
- Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)CompletedPhase 2Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01591863Written as fidaxomicin
- Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile InfectionWithdrawnPhase 4University of Colorado, DenverNCT02464306Written as fidaxomicin
- Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus VancomycinCompletedPhase 4Hartford HospitalNCT01818141Written as Fidaxomicin
- PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)CompletedPhase 3Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00468728Written as PAR-101/OPT-80
- Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)CompletedPhase 3Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00314951Written as Fidaxomicin
- OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)CompletedPhase 2Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00097422Written as OPT-80
- Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord InjuryTerminatedPhase 4Baylor College of MedicineNCT02355938Written as Fidaxomicin 200 mg
See all 23 studies that test Fidaxomicin →
As the comparator · 4 — what is tested is compared with Fidaxomicin
- Vancomycin Taper to Prevent Recurrent Clostridioides DifficileRecruitingPhase 3McGill University Health Centre/Research Institute of the McGill University Health CentreNCT07328971Written as Fidaxomicin
- Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs FidaxomicinCompletedPhase 3Mikrobiomik Healthcare Company S.L.NCT05201079Written as Fidaxomicin
- Fecal Microbiota Transplantation for Relapsing Clostridium Difficile InfectionCompletedPhase 3University of AarhusNCT02743234Written as Fidaxomicin
- A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)CompletedPhase 2Summit TherapeuticsNCT02784002Written as Fidaxomicin
Codes
What other systems call Fidaxomicin · ClinicalTrials.gg INT006797
- MeSH (NLM) D000077732FidaxomicinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Z5N076G8YQFIDAXOMICINConfirmed FDA, NLM, Wikidata
- RxNorm 1111103One source FDA
- Wikidata Q111242331fidaxomicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66979FidaxomicinOne source FDA
- DrugBank DB08874One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077732 | Fidaxomicin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Z5N076G8YQ | FIDAXOMICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1111103 | — | One source FDA |
| Wikidata | Q111242331 | fidaxomicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66979 | Fidaxomicin | One source FDA |
| DrugBank | DB08874 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.